Publications
Jaishankar P, Correy GJ, Matsui Y, Togo T, Rachman MM, Stevens MGV, Hantz ER, Zheng J, Diolaiti ME, Montano M, Taha TY, Rosecrans J, Pampel J, Krogan NJ, Shoichet BK, Ashworth A, Ott M, Fraser JS, Renslo AR. Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo. Journal of medicinal chemistry. 2025. PMID: 41406955
Ayo-Ajibola O, Jung T, Razura DE, Gallagher TJ, Lin ME, Angell TE, Kwon DI. Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use. Journal of the Endocrine Society. 2025. PMID: 41476725
Nyagabona SK, Haddadi S, Mtei RJ, Sunguya B, Kahesa C, Pallangyo CK, Wang CJ, Van Loon K, Mmbaga EJ. Paving the Way for an Integrated Care Model: Experiences of Women Living With HIV and Breast Cancer in Tanzania. JCO global oncology. 2025. PMID: 41397196
Huang M, Chen Y, Liang C, Narayan OP, Stallings C, Yu M, Traugot C, Li L, Li K, Vo Q, Wang H, Chou YT, Cech L, Parra D, Garzon L, Parsons D, Diaz E, Zhang C, Mackey C, Sussman H, Zmirska I, Chung M, Zhou C, Glynatsis G, Siemann DW, Licht JD, Li C, Kaye FJ, Xie M, Tan Y, Wu L, Bivona TG, Guan J, Tang X. Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerability. Biomaterials. 2025. PMID: 41443038
Jung H, Devant P, Ching C, Ota M, Hamilton J, Steinhart Z, Ngo W, Sandoval L, Jung JH, Xu D, An M, Urs E, Chen PA, Allain V, Tada T, Nuñez JK, Landau NR, Liu DR, Eyquem J, Doudna JA, Marson A, Carnevale J. Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells. bioRxiv : the preprint server for biology. 2025. PMID: 41415457
Brondfield S, O'Brien B, Rangachari D. Modernizing Medical Education: Educational Strategies to Meet Emerging Needs in Hematology/Oncology. JCO oncology practice. 2025. PMID: 41385759
Loren AW, Lacchetti C, Amant F, Cardonick EH, Carey LA, Christian N, Clark C, Dizon DS, Henry M, Hudson MH, Maués J, Peterson E, Prowell TM, Raab R, Rogers JE, Saeed H, Sekeres MA, Taylor JS, Van Loon K, Wallace WH, Watson KL, Yadav S, Partridge AH. Management of Cancer During Pregnancy: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 41380115
Uwamahoro P, Girukubonye I, Bigirimana JB, Shyirambere C, Van Loon K, Sudore RL, Sanders JJ, Cubaka VK, DeBoer RJ. Correction: Setting the stage for communication skills training in Rwandan cancer care: a qualitative study of local priorities and key contextual factors. BMC palliative care. 2025. PMID: 41372995
Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nature communications. 2025. PMID: 41365872
Kilari D, Henderson NC, Yamamoto K, Yao Y, Hwang C, Barata PC, Bilen MA, Graham L, Garje R, Rothstein S, Haider S, Park JJ, Raychaudhuri R, Pilling A, Chin E, Koshkin VS, Tripathi A, Cackowski FC, Nauseef JT, Sokolova A, Ayanambakkam A, Zakharia Y, Schweizer MT, Armstrong AJ, Dorff TB, Reichert ZR, McKay RR. Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer. JCO precision oncology. 2025. PMID: 41348987
Kayraklioglu N, Zhang L, Cornelia Ding CK, Greenland NY, Stohr BA, Koshkin VS, Simko JP, Sirohi D. Correlation of Lymphocytic Infiltration and Degree of Pleomorphism with Tumor Mutation Burden in High-Grade Urothelial Carcinoma. Human pathology. 2025. PMID: 41354158
Kayraklioglu N, Zhang L, Cornelia Ding CK, Greenland NY, Stohr BA, Koshkin VS, Simko JP, Sirohi D. Correlation of Lymphocytic Infiltration and Degree of Pleomorphism with Tumor Mutation Burden in High-Grade Urothelial Carcinoma. Human pathology. 2025. PMID: 41354158
Iyengar NM, O'Shaughnessy JA, Moore HN, Hamilton E, Jhaveri KL, Ma CX, Tedesco K, Vasekar M, Donahue S, Rugo HS. Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion. NPJ breast cancer. 2025. PMID: 41345397
Jacob S, Fisch S, Face C, Blum K, Chengappa M, Chaudhry S, LeVee A, Baclig NV, Soliman A, Huppert LA, Quandt Z, Quintal L, Idossa D, Melisko M, Chien AJ, Kim MO, Mortimer J, McCann K, Blaes A, Rugo HS. Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer. NPJ breast cancer. 2025. PMID: 41339346
Jacob S, Fisch S, Face C, Blum K, Chengappa M, Chaudhry S, LeVee A, Baclig NV, Soliman A, Huppert LA, Quandt Z, Quintal L, Idossa D, Melisko M, Chien AJ, Kim MO, Mortimer J, McCann K, Blaes A, Rugo HS. Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer. NPJ breast cancer. 2025. PMID: 41339346
Dercle L, Geyer S, Nixon AB, Innocenti F, Shi Q, Jacobson SB, Luk L, Liu A, Yang H, Wen Y, Zhao B, Eche T, Mokrane FZ, Yang M, Meyerhardt J, O'Reilly EM, Venook AP, El-Khoueiry AB, Schwartz LH, Abou-Alfa GK. Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance). ESMO open. 2025. PMID: 41337859
De Souza AL, Hadfield MJ, Lu S, Golijanin DJ, Wood R, Margolis J, Anderson K, Olszewski AJ, Holder SL, El-Deiry WS, Aggarwal RR, Mega AE, Carneiro BA. BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Cancer Research Communications. 2025. PMID: 41231232
Goretsky Y, Holtzman N, Han S, Reis IM, Suzuki V, Jean P, Mones K, Diaz-Paez M, Benjamin C, Beitinjaneh A, Goodman M, Jimenez AJ, Lekakis L, Pereira D, Spiegel J, Wu Y, Green DJ, Komanduri KV, Wang TP. Extracorporeal Photopheresis for Chronic Graft-Versus-Host Disease According to 2014 NIH Consensus Criteria. Journal of clinical apheresis. 2025. PMID: 41277038
Ko AH. Comprehensive Genomic Profiling for Resectable Pancreatic Cancer: The Earlier the Better? JCO oncology practice. 2025. PMID: 41289544
Chatterjee A, Mustafa Ali MK, Bailey CM, Liu Y, Small D, Smith CC, Traer E, Wang Y, Silvestri G, Baer MR. Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors. bioRxiv : the preprint server for biology. 2025. PMID: 41341164